<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899869</url>
  </required_header>
  <id_info>
    <org_study_id>INT_TN_001</org_study_id>
    <nct_id>NCT04899869</nct_id>
  </id_info>
  <brief_title>Faecal Microbiota Transplantation in Irritable Bowel Syndrome</brief_title>
  <acronym>MISCEAT</acronym>
  <official_title>Faecal Microbiota Transplantation in Irritable Bowel Syndrome: a Randomised, Double-blind Cross-over Study Utilising Mixed Microbiota From Healthy Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomayer University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomayer University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irritable bowel syndrome (IBS) is the most common functional bowel disorder, being present in&#xD;
      approximately 10% of adult Europoid population. The etiology of IBS is elusive. Literature&#xD;
      indicates that modification of patientsÂ´colonic microbiota might ameliorate the condition.&#xD;
      Here we test an intervention by faecal microbiota transplantation of artificially inflated&#xD;
      microbiome diversity, versus autoclaved placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Three-groups, double-blind, placebo-controlled, randomised, cross-over study in adult&#xD;
      patients diagnosed with IBS (diarrhoeal or mixed form) according to Rome IV criteria. Each&#xD;
      study subject will undergo two pairs of faecal microbiota transplantation (a total of four&#xD;
      enemas for each patient), with the pairs of transfers being eight weeks apart. The active&#xD;
      intervention substance is a mixed stool microbiota derived from healthy individuals, screened&#xD;
      for infectious diseases according to European consensus conference on faecal microbiota&#xD;
      transplantation guidelines, and who were preselected for high alpha diversity of their&#xD;
      microbiome and distance in community ordination from IBS patients microbiota. Placebo is the&#xD;
      same mixture, inactivated by autoclaving.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 17, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Each study subject will undergo two pairs of faecal microbiota transplantation eight weeks apart (a total of four enemas for each patient). Our study design has several specific features: (a) Two consecutive transfers were designed to improve study microbiota engraftment. Before the first of every transfer pairs, the subjects will receive a reduced dose of oral polyethylene glycol for partial bowel preparation. (b) To help discern potential carry-over effects, a placebo-only group was included; this also enables us to assess long-term effects of the intervention. (c) The transferred microbiota is identical throughout the study, having been mixed beforehand, aliquoted and deep frozen. Its alpha diversity was artificially increased by mixing stools from several donors. (d) Placebo is made of the same mixture by careful autoclaving.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the IBS severity symptom score (IBS-SSS)</measure>
    <time_frame>The difference between the score at four weeks after the intervention (study weeks 5 or 13, respectively) and the baseline (week -1 in 'Active microbiota first' group or week 8 in 'Inactive microbiota first' group)</time_frame>
    <description>Change in the IBS severity symptom score (IBS-SSS) during the active microbiota treatment period relative to the placebo treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The acute change in the IBS severity symptom score</measure>
    <time_frame>study weeks 3 and 11</time_frame>
    <description>IBS-SSS between baseline and two weeks after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The long-term change in the IBS severity symptom score</measure>
    <time_frame>baseline and study week 32</time_frame>
    <description>IBS-SSS between baseline and week 32 in 'Inactive microbiota only' group versus 'Active microbiota first' group + 'Inactive microbiota first' group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Irritable Bowel Syndrome With Diarrhea</condition>
  <condition>Irritable Bowel Syndrome Mixed</condition>
  <arm_group>
    <arm_group_label>Active microbiota first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will first receive two enemas of active study microbiota mixture (deep-frozen stored stool microbiota mixed from eight donors in order to increase its diversity), then after eight weeks they will receive two enemas with placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive microbiota first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will first receive placebo, then the active study microbiota mixture.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactive microbiota only</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive similarly timed enemas with placebos only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Faecal microbiota transplantation with active study microbiota first</intervention_name>
    <description>2x enema with active study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota</description>
    <arm_group_label>Active microbiota first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Faecal microbiota transplantation with inactive autoclaved study microbiota first</intervention_name>
    <description>2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with active study microbiota</description>
    <arm_group_label>Inactive microbiota first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Faecal microbiota transplantation with inactive autoclaved study microbiota only</intervention_name>
    <description>2x enema with inactive autoclaved study microbiota; after 8 wks 2x enema with inactive autoclaved study microbiota</description>
    <arm_group_label>Inactive microbiota only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) or Irritable Bowel Syndrome with&#xD;
             mixed bowel habits (IBS-M) according to the Rome IV criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The use of antibiotics within one month prior to faecal microbiota transplantation&#xD;
&#xD;
          -  The use of probiotics within one month prior to faecal microbiota transplantation&#xD;
&#xD;
          -  History of inflammatory bowel disease or gastrointestinal malignancy, systemic&#xD;
             autoimmune diseases (ongoing or in history)&#xD;
&#xD;
          -  Previous abdominal surgery (other than appendectomy or cholecystectomy or hernioplasty&#xD;
             or cesarean section)&#xD;
&#xD;
          -  HIV infection or other active infection&#xD;
&#xD;
          -  Renal or hepatic disease (both defined by biochemistry workup)&#xD;
&#xD;
          -  Diabetes mellitus, abnormal thyroid functions not controlled by thyroid medications&#xD;
&#xD;
          -  Bipolar disorder or schizophrenia (ongoing or history thereof), moderately severe&#xD;
             depression defined by Patient Health Questionnaire-9 (PHQ-9) score &gt; 15&#xD;
&#xD;
          -  Anxiety defined by a Generalised Anxiety Disorder 7 (GAD7) score &gt; 10&#xD;
&#xD;
          -  Current pregnancy and lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel Kohout</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomayer University Hospital, Prague, Czech Republic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiri Vejmelka</last_name>
    <phone>00420731446619</phone>
    <email>jiri.vejmelka@ftn.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomayer University Hospital</name>
      <address>
        <city>Prague</city>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiri Vejmelka</last_name>
      <phone>00420731446619</phone>
      <email>jiri.vejmelka@ftn.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thomayer University Hospital</investigator_affiliation>
    <investigator_full_name>Pavel Kohout</investigator_full_name>
    <investigator_title>Pavel Kohout, Assoc. Prof., MD, PhD.</investigator_title>
  </responsible_party>
  <keyword>IBS - D, IBS - M</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

